Disc Medicine presents updated positive RALLY-MF Phase 2 data
Disc-0974 showed consistent hepcidin reduction and robust anemia responses across all subgroups, with 55% of non-transfusion dependent patients achieving major hemoglobin response.
See the latest news and media coverage for Disc Medicine. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing hematology treatments
discmedicine.comLast updated
In short: Disc Medicine advanced its clinical pipeline and navigated regulatory shifts regarding bitopertin while maintaining a strong financial position.
Disc-0974 showed consistent hepcidin reduction and robust anemia responses across all subgroups, with 55% of non-transfusion dependent patients achieving major hemoglobin response.
Cash at $730M funds into 2029. Completed Phase 3 enrollment for bitopertin in EPP; data expected Q4 2026. Updates on DISC-0974 and DISC-3405 trials.
Data from DISC-0974 trial in myelofibrosis patients with anemia will be presented at ASCO Annual Meeting on June 2, 2026.
The last participant is dosed in the Phase 3 trial of bitopertin for EPP. Results are expected in Q4 2026.
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ...
Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.
Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.
York--(Newsfile Corp. - June 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf...
Track Disc Medicine and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Disc Medicine and other trending companies.